<DOC>
	<DOCNO>NCT00724529</DOCNO>
	<brief_summary>The purpose study understand safety effectiveness infliximab use clinical practice . This post-marketing surveillance study .</brief_summary>
	<brief_title>Post Marketing Surveillance Remicade</brief_title>
	<detailed_description>The investigator record continuously first patient since day contract number patient contract base Remicade approval .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Severe active Crohn 's disease : patient severe active Crohn 's disease show response treatment corticosteroid immunosuppressive agent , drug tolerance , contraindicate treatment . Fistulatype active Crohn 's disease : patient fistulatype active Crohn 's disease show response general treatment antibiotic , drainage , immunosuppressant . Ankylosing spondylitis : patient ankylose spondylitis show adequate response general treatment , increase serological index relate severe axial symptom inflammation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Ankylosing Spondylitis</keyword>
</DOC>